APLI — Appili Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$1.99m
- CA$14.23m
- CA$0.10m
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez
Brief: Appili President And CEO, Don Cilla To Join Aditxt CEO, Amro Albanna For Aditxt Weekly Update On April 4, 2025
Aditxt more than doubles after Appili takeover deadline extended
Brief: Appili Therapeutics Announces Submission Of US Federal Government Funding Proposals And Provides Corporate And Aditxt Transaction Update
Brief: Appili Therapeutics Announces Receipt Of Final Court Order For Arrangement With Aditxt, Inc.
Brief: Aditxt Provides Update On Equity Line Of Credit, ATM Usage, And Outstanding Number Of Shares
Brief: Aditxt’s Target Acquisition Appili Therapeutics Announces Results Of Special Meeting Of Shareholders
Brief: Aditxt’S Target Acquisition Appili Therapeutics Announces Alignment With FDA On Development Requirements For ATI-1801 Topical Antiparasitic Product NDA Submission
Brief: Appili Therapeutics Announces Alignment With FDA On Development Requirements For Ati-1801 Topical Antiparasitic Product NDA Submission
Brief: Appili Therapeutics Presents Update On ATI-1701 Biodefense Vaccine Candidate At IDWeek™ 2024
Brief: Aditxt Signs Second Amendment Arrangement Agreement With Appili Therapeutics
Brief: Appili Therapeutics Says Increases Bridge Loan To C$400,000
Brief: Appili Therapeutics Signs Definitive Agreement To Be Acquired By Aditxt Inc
Brief: Appili Therapeutics Announces Issuance Of Patent For ATI-1701 Biodefense Vaccine Candidate And Provides Update On Bridge Loan
Brief: Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 Awarded Additional Funding From U.S. Air Force Academy
Canada's Appili gets US FDA approval for oral antibiotic solution (updated)